Single agent and combination studies of pralatrexate and molecular correlates of sensitivity.
Serova M, Bieche I, Sablin MP, Pronk GJ, Vidaud M, Cvitkovic E, Faivre S, Raymond E. Br J Cancer . 2011;104(2):272-80.
Publications 2000-2011
Ghoul A, Serova M, Astorgues-Xerri L, Bieche I, Bousquet G, Varna M, Vidaud M, Phillips E, Weill S, Benhadji KA, Lokiec F, Cvitkovic E, Faivre S, Raymond E.
Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells. Cancer Res. 2009 May 15; 69(10):4260-9.
Serova M, Astorgues-Xerri L, Bieche I, Albert S, Vidaud M, Benhadji KA, Emami S, Vidaud D, Hammel P, Theu-Anton N, Gespach C, Faivre S, Raymond E.
Epithelial-to-Mesenchymal Transition and Oncogenic Ras Expression in Resistance to the Protein Kinase Cß Inhibitor Enzastaurin in Colon Cancer Cells. Mol Cancer Ther. 2010 May;9(5):1308-17.
Lovejoy KS, Serova M, Bieche I, Emami S, D'Incalci M, Broggini M, Erba E, Gespach C, Cvitkovic E, Faivre S, Raymond E, Lippard SJ.
Spectrum of cellular responses to pyriplatin, a monofunctional cationic antineoplastic platinum(II) compound, in human cancer cells. M ol Cancer Ther. 2011;10(9):1709-19.
Serova M, Ghoul A, Rezai K, Lokiec F, Cvitkovic E, Nowotnik D, Faivre S and Raymond E.
In vitro Antiproliferative. Effects of ProLindac™, a Novel Dach-Platinum-Linked Polymer Compound, as a Single Agent and in Combination with Other Anti-cancer Drugs Chapter in book “Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy”, Humana Press, 2009, P.41-48.
Nowotnik DP, Cvitkovic E.
ProLindac (AP5346): a review of the development of an HPMA DACH platinum Polymer Therapeutic. Adv Drug Deliv Rev. 2009 Nov 12;61(13):1214-9 . Review.
Le Tourneau C, Faivre S, Serova M, Raymond E.
mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work? Br J Cancer. 2008 Oct 21; 99(8):1197-203.
Serova M , Ghoul A, Benhadji KA, Faivre S, Le Tourneau C, Cvitkovic E, Lokiec F, Lord J, Ogbourne SM, Calvo F, Raymond E.
Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells. Mol Cancer Ther. 2008 Apr; 7(4):915-22.
Tredaniel J, Becht C, Bekradda M, De Cremoux H, Alexandre J, Chomy F, Szyldergemain S, Yataghene Y, Culine S.
An Open Phase II Trial of Gemcitabine, Oxaliplatin and Vinorelbine Combination as First-Line Therapy in advanced Non-Small Cell Lung Cancer Patients. Lung Cancer 2009; 63 (2): 259-263
Benhadji KA, Serova M, Ghoul A, Cvitkovic E, Le Tourneau C, Ogbourne SM, Lokiec F, Calvo F, Hammel P, Faivre S, Raymond E.
Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells. Br J Cancer. 2008 Dec 2; 99(11):1808-15.
Alexandre J, Kahatt C, Bertheault-Cvitkovic F, Faivre S, Shibata S, Hilgers W, Goldwasser F, Lokiec F, Raymond E, Weems G, Shah A, MacDonald JR, Cvitkovic E.
A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors. Invest New Drugs. 2007 Oct; 25(5):453-62.
Aissat N, Le Tourneau C, Ghoul A, Serova M, Bieche I, Lokiec F, Raymond E, Faivre S.
Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol. 2007 Oct 2.
Clikeo 